These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36277429)

  • 1. Circulatory cytokeratin 17, marginal zone B1 protein and leucine-rich α2-glycoprotein-1 as biomarkers for disease severity and fibrosis in systemic sclerosis patients.
    Bălănescu P; Bălănescu E; Băicuș C; Bălănescu A
    Biochem Med (Zagreb); 2022 Oct; 32(3):030707. PubMed ID: 36277429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High serum levels of YKL-40 in patients with systemic sclerosis are associated with pulmonary involvement.
    Nordenbaek C; Johansen JS; Halberg P; Wiik A; Garbarsch C; Ullman S; Price PA; Jacobsen S
    Scand J Rheumatol; 2005; 34(4):293-7. PubMed ID: 16195162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on biomarker discovery and use in systemic sclerosis.
    Matsushita T; Takehara K
    Expert Rev Mol Diagn; 2017 Sep; 17(9):823-833. PubMed ID: 28730919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The involvement of leucine-rich α-2 glycoprotein in the progression of skin and lung fibrosis in bleomycin-induced systemic sclerosis model.
    Nakajima H; Nakajima K; Serada S; Fujimoto M; Naka T; Sano S
    Mod Rheumatol; 2021 Nov; 31(6):1120-1128. PubMed ID: 33535851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in the Pathogenesis, Diagnosis, and Treatment of Systemic Sclerosis.
    Muruganandam M; Ariza-Hutchinson A; Patel RA; Sibbitt WL
    J Inflamm Res; 2023; 16():4633-4660. PubMed ID: 37868834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum levels and tissue expression of matrix metalloproteinase-12 in patients with systemic sclerosis: correlation with severity of skin and pulmonary fibrosis and vascular damage.
    Manetti M; Guiducci S; Romano E; Bellando-Randone S; Conforti ML; Ibba-Manneschi L; Matucci-Cerinic M
    Ann Rheum Dis; 2012 Jun; 71(6):1064-72. PubMed ID: 22258486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candidate proteomic biomarkers in systemic sclerosis discovered using mass-spectrometry: an update of a systematic review (2014-2020).
    Bălănescu P; Bălănescu A; Bălănescu E; Băicuş C
    Rom J Intern Med; 2021 Jun; 59(2):101-111. PubMed ID: 33565304
    [No Abstract]   [Full Text] [Related]  

  • 8. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis.
    Motta F; Tonutti A; Isailovic N; Ceribelli A; Costanzo G; Rodolfi S; Selmi C; De Santis M
    Front Immunol; 2023; 14():1246777. PubMed ID: 37753072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Leucine-Rich α2-Glycoprotein-1 Levels in Patients with Multiple Myeloma.
    Kaçmaz M; Oğuzman H
    Oncol Res Treat; 2023; 46(10):415-423. PubMed ID: 37527638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surfactant protein D (SP-D) and systemic scleroderma (SSc).
    Maeda M; Ichiki Y; Aoyama Y; Kitajima Y
    J Dermatol; 2001 Sep; 28(9):467-74. PubMed ID: 11603386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis.
    Yayla ME; İlgen U; Okatan İE; UsluYurteri E; Torgutalp M; Keleşoğlu Dinçer AB; Aydemir Gülöksüz EG; Sezer S; Turgay TM; Kınıklı G; Ateş A
    Clin Rheumatol; 2020 Jan; 39(1):77-83. PubMed ID: 31317426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of plasma identifies the Toll-like receptor agonists S100A8/A9 as a novel possible marker for systemic sclerosis phenotype.
    van Bon L; Cossu M; Loof A; Gohar F; Wittkowski H; Vonk M; Roth J; van den Berg W; van Heerde W; Broen JC; Radstake TR
    Ann Rheum Dis; 2014 Aug; 73(8):1585-9. PubMed ID: 24718960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoantibodies against PIP4K2B and AKT3 Are Associated with Skin and Lung Fibrosis in Patients with Systemic Sclerosis.
    Geroldinger-Simić M; Bayati S; Pohjanen E; Sepp N; Nilsson P; Pin E
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of affected and unaffected areas of systemic sclerosis skin biopsies by high-throughput proteomic approaches.
    Chairta P; Nicolaou P; Sokratous K; Galant C; Houssiau F; Oulas A; Spyrou GM; Alarcon-Riquelme ME; Lauwerys BR; Christodoulou K
    Arthritis Res Ther; 2020 May; 22(1):107. PubMed ID: 32381114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
    Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
    Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [THE ROLE OF SEMAPHORIN 7A IN SYSTEMIC SCLEROSIS].
    Rimar D; Slobodin G; Rosner I; Rozenbaum M; Kaly L; Boulman N; Jiries N; Awisat A; Vadasz Z
    Harefuah; 2017 Jul; 156(7):418-421. PubMed ID: 28786275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated plasma and vitreous levels of leucine-rich-α2-glycoprotein are associated with diabetic retinopathy progression.
    Chen C; Chen X; Huang H; Han C; Qu Y; Jin H; Niu T; Zhang Y; Liu K; Xu X
    Acta Ophthalmol; 2019 May; 97(3):260-264. PubMed ID: 29168314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between vascular biomarkers and disease characteristics in systemic sclerosis: elevated MCP-1 is predominantly associated with fibrotic manifestations.
    Yalçinkaya Y; Çinar S; Artim-Esen B; Kamali S; Öcal L; Deniz G; Inanç M
    Clin Exp Rheumatol; 2016; 34 Suppl 100(5):110-114. PubMed ID: 27749243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.